Eurofins Cerep Stock Euronext Paris
Equities
FR0012045946
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
04-30 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Sales 2022 | 47.65M 51.48M 70.8M | Sales 2023 | 44.07M 47.61M 65.49M | Capitalization | 126M 136M 187M |
---|---|---|---|---|---|
Net income 2022 | 11M 11.88M 16.34M | Net income 2023 | 7M 7.56M 10.4M | EV / Sales 2022 | 2.08 x |
Net cash position 2022 | 12.81M 13.84M 19.03M | Net cash position 2023 | 8.63M 9.32M 12.82M | EV / Sales 2023 | 2.67 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-
| Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 4.22% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 18-04-18 | |
Damien Séroux
CHM | Chairman | - | 14-10-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Damien Séroux
CHM | Chairman | - | 14-10-12 |
Director/Board Member | 68 | 15-06-09 | |
Chief Executive Officer | - | 18-04-18 |
1st Jan change | Capi. | |
---|---|---|
+53.21% | 59.28B | |
+41.42% | 40.94B | |
-5.48% | 40.17B | |
-5.16% | 28.69B | |
+12.68% | 26.63B | |
-20.54% | 18.89B | |
+30.75% | 12.46B | |
+0.21% | 12.42B | |
+26.25% | 12.26B |